LAUSANNE, Switzerland– Saphetor, a global precision medicine company and the creator of VarSome, The Human Genomics Community and variant interpretation platform, announced today a partnership with) PTC Therapeutics International Limited. The open genomics community, VarSome.com, brings together a vast global network of clinical and research genetic laboratories leveraging its industry-leading genomic annotation tools and data. The collaboration will be centered around supporting awareness of clinical programs in rare diseases.
With this partnership, Saphetor will facilitate connecting the rare disease community to accelerate research collaboration, by identifying the most relevant stakeholders and facilitating the communication between involved parties such as labs, pharma and healthcare professionals. This collaboration will help improve the speed at which the rare disease community can be made aware of rare diseases and associated clinical programs, relevant to their genes / variants of interest thanks to VarSome’s global coverage of users.
Ludovic Baillon, Genetic and Diagnostic Lead, at PTC Therapeutics said: “We look forward to leveraging Saphetor’s innovative approach to bring together the global genomics community to build awareness in our rare disease programs”.
Andy Cosgrove, CCO of Saphetor commented: “We are very excited to partner with PTC Therapeutics and contribute to their important effort in developing treatments in rare diseases. VarSome.com is proving an extremely valuable resource for willing clinical and research labs as well as pharmaceutical companies to collaborate on a worldwide level”.
